Research and development

News from research

Here you will find recent information on our R&D projects. An overview of our most recent announcements on the progress and results of clinical trials and our latest scientific medical publications are shown here.

Older reports can be found in the archive.

 

Latest news

Solid Tumor Study No. 989 with BT-062 still ongoing

After various inquiries presumable triggered by information in the EU Clinical Trials Register Biotest AG wants to clarify that the Phase I/IIa study with BT-062 in the indications triple negative metastatic breast cancer and metastatic bladder cancer is still ongoing. ... [More]

Pentaglobin(R) showed a significant survival benefit i...

23.05.2016, News

Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria - Additional therapy with Pentaglobin(R) significantly reduced the relative ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014, News

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th ... [More]

Biotest AG starts combination therapy study with BT-06...

16.07.2012, News

Biotest AG starts combination therapy study with BT-062 in multiple myeloma - Antibody-drug conjugate BT-062 continues to show good tolerability in monotherapy - First patient treated in ... [More]

Biotest announces clinical trial data for its new inves...

11.04.2012, News

Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US market Dreieich, 11 April 2012. Biotest AG announces the publication of its ... [More]

Monoclonal antibody BT-061 shows efficacy in the indica...

17.03.2010, News

Monoclonal antibody BT-061 shows efficacy in the indication psoriasis - Final results of Phase I/IIa trial in chronic plaque psoriasis show long- lasting therapeutic effect after a single ... [More]